comprehensive -WSS

comprehensive

author：leisure time 2025-09-03 11:51:25 - browse：752

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

WSS

Congress: Eradicate hepatitis C and reduce the deficit

New Covid vaccine is recommended for everyone 6 months or older

Woman gored by Bison at Yellowstone

Congress likely to miss an opportunity to fix drug shortages issue

What to make of Biden’s latest efforts on cancer research

The new HIV moral panic

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical leaders decry Supreme Court decision on affirmative action

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Guidelines to prevent youth baseball injuries need more muscle

What to make of Biden’s latest efforts on cancer research

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to make the FDA’s new prescription one

Anesthesiologist group: stop taking Ozempic before surgery

Diverse clinical trials: Why aren’t we there yet?

Bright Health sells Medicare Advantage business to Molina

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

focus

Federal judge rules Oregon’s tough new gun law is constitutional

Private equity could exacerbate cardiology's overuse problem, experts fear

Popular nasal decongestant doesn't actually relieve congestion

WATCH: Why do bright lights make us see spots?

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Mike Pence clashes with Tucker Carlson in Iowa

leisure time

Wikipedia

focus

focus